Medifocus Inc. Announces Equity Offering
(firmenpresse) - COLUMBIA, MD and TORONTO, ON -- (Marketwired) -- 03/27/15 -- (OTCQX: MDFZF) (TSX VENTURE: MFS) announces, subject to regulatory approval, a non-brokered private placement of up to 40,454,546 common shares (the ) at a price of $0.055 per Common Share for gross proceeds of up to $2,225,000 (the ). The net proceeds of the Offering will be used for general working capital. Medifocus anticipated that the Offering will be completed on or around April 2, 2015. Medifocus may pay finder''s fees equal to 9% of the gross proceeds raised.
Medifocus owns two fully developed technology platforms with comprehensive United States and international patent protection: (i) The Endo-thermotherapy Platform-a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites. The United States Food and Drugs Administration (FDA) approved Prolieve® Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (BPH) was developed based on the Endo-thermotherapy and is currently generating revenue; and (ii) the Adaptive Phased Array (APA) Microwave Focusing Platform, invented by the Massachusetts Institute of Technology, licensed to Medifocus directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. Medifocus'' APA 1000 Breast Cancer Treatment System, developed from the APA technology platform, has received approval from the FDA and Health Canada to conduct the pivotal Phase III clinical trials. Medifocus believes that these two technology platforms can provide the design basis for the development of multiple cancer treatment systems for surface, subsurface and deep seated localized and regional cancers.
Please visit , and for more details.
This news release contains "forward-looking statements" and "forward-looking information", which may not be based on historical facts. Forward-looking statements and forward-looking information, include, but are not limited to, information and statements with respect the structure and the proceeds of the Offering and the expected use of the proceeds. Forward-looking statements are frequently characterized by words such as "plan," "expect," "project," "intend," "believe," "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made. Such forward-looking statements and forward-looking information involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or forward-looking information. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements and forward-looking information. Except as required by applicable securities laws, Medifocus disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results, events or developments.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
John Mon
COO
Medifocus, Inc.
Tel: 410-290-5734
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 27.03.2015 - 15:22 Uhr
Sprache: Deutsch
News-ID 1347388
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
COLUMBIA, MD and TORONTO, ON
Phone:
Kategorie:
Trials
Anmerkungen:
Diese Pressemitteilung wurde bisher 283 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medifocus Inc. Announces Equity Offering
"
steht unter der journalistisch-redaktionellen Verantwortung von
Medifocus, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
